CN102000098B - The purposes of ginsenoside Rg1 - Google Patents
The purposes of ginsenoside Rg1 Download PDFInfo
- Publication number
- CN102000098B CN102000098B CN201010543658.9A CN201010543658A CN102000098B CN 102000098 B CN102000098 B CN 102000098B CN 201010543658 A CN201010543658 A CN 201010543658A CN 102000098 B CN102000098 B CN 102000098B
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- purposes
- cgmp
- mice
- spongy body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 title claims abstract description 24
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 title claims abstract description 16
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 208000012201 sexual and gender identity disease Diseases 0.000 claims abstract description 4
- 208000015891 sexual disease Diseases 0.000 claims abstract description 4
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 5
- 239000000178 monomer Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 abstract description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 6
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000027326 copulation Effects 0.000 description 4
- 230000009329 sexual behaviour Effects 0.000 description 4
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101150098694 PDE5A gene Proteins 0.000 description 3
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 3
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000010413 mother solution Substances 0.000 description 3
- 229940083618 sodium nitroprusside Drugs 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150085511 PEDS1 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102100037592 Plasmanylethanolamine desaturase Human genes 0.000 description 1
- 101150095510 TMEM35A gene Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007758 mating behavior Effects 0.000 description 1
- 229960002931 methacholine chloride Drugs 0.000 description 1
- JHPHVAVFUYTVCL-UHFFFAOYSA-M methacholine chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(C)=O JHPHVAVFUYTVCL-UHFFFAOYSA-M 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920003199 poly(diethylsiloxane) Polymers 0.000 description 1
- 150000004032 porphyrins Chemical group 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000000079 presaturation Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the novelty teabag of ginsenoside Rg1, especially prevention or treatment male sexual disorder as erection disturbance in purposes.
Description
Invention field
The present invention relates to the novelty teabag of ginsenoside Rg1, especially prevention or treatment male sexual disorder as erection disturbance in purposes.
Background technology
Ginsenoside Rg1 is a kind ofly present in many plants as the known chemical monomer in Radix Ginseng.Its structure and be biological activities associatedly reported in relevant textbooks or delivered in document.But the purposes that ginsenoside Rg1 is preventing and/or treating male's sexual direction is not reported so far.
Summary of the invention
The present inventor now finds that ginsenoside Rg1 is by suppressing di-phosphate ester ester V (PDE after deliberation
v) and improve CGMP concentration, thus promote spongy body erection function.
Therefore, first aspect present invention relates to ginsenoside Rg1 purposes in for the preparation of the product preventing and/or treating sexual dysfunction.
Further aspect of the present invention relates to the product for preventing and/or treating sexual dysfunction, and it comprises panaxoside monomer and excipient or carrier.
According to the present invention, term " sexual dysfunction " citing is said and be can be erection disturbance.
In the present invention, product list says functional food or medicine.
According to the present invention, ginsenoside Rg1 prepares by commercially available or known method.Product of the present invention is by being mixed with ginsenoside Rg1 and excipient or carrier.
Accompanying drawing explanation
Fig. 1 a straddles result for giving ginsenoside Rg1 mice.
Fig. 1 b is for giving ginsenoside Rg1 mice number of copulations.
Detailed description of the invention
The following examples are used for further illustrating the present invention, but it does not mean that any limitation of the invention.
Materials and methods
Animal
Kunming mice, 36-38g, female, hero provides by Chinese Academy of Medical Sciences's Experimental Animal Center.New zealand white rabbit, 2.5-3kg, male, provided by PLA General Hospital Experimental Animal Center.Room temperature 18-22 DEG C, illumination 12hr: 12hr (light: dark), uses prospective adaptation environment 3 days.
Reagent and preparation
Methacholine chloride (MCH), sodium nitroprusside (sodium nitroprusside, SNP) purchased from Sigma, phenylephrine hydrochloride inj (PE), Shanghai City Tian Feng pharmaceutical factory produces, DMEM is purchased from Gibco BRL company, cGMP measures test kit purchased from Chinese Atomic Energy Research Institute, panaxoside monomer Rg1, Rb1 (content > 98%), thered is provided by Norman Bethune Medical University's Organic Chemistry Laboratory, NO mensuration test kit builds up Bioengineering Research Institute by Nanjing to be provided, testosterone measures test kit purchased from Shanghai Biological Products Inst., Ministry of Public Health.All the other reagent are domestic analytical pure.Nutritional solution forms: sodium chloride 118.2, potassium chloride 2, potassium dihydrogen phosphate 0.5, calcium chloride 0.7, sodium bicarbonate 25, glucose 11.1m molL
-1, compound method: CaCl
2after being baked to constant weight, be first made into the mother solution that concentration is application liquid 100 times; NaCHO
3, glucose takes before use, adds nutritional solution; The mother solution that concentration is application liquid 20 times is made into after the mixing of other compositions.Mother solution dilutes before use, adjusts PH to 7.4, passes to 95%O
2, 5%CO
2the presaturation of mixing oxygen stand-by.
Instrument and equipment
Thermostatic water-circulator bath HSZ-H, Harbin Dong Lian electronic technology development corporation, Ltd. product, tonotransducer LW-10 is purchased from Shanghai red flag instrucment and meter plant, monitor TYPE-3066 is Japanese Shimadzu Corporation product, β liquid scintillation counter LS9800 is Beckman Products, and homogenizer is purchased from LITTAU-LUZERN factory of Sweden, and refrigerated centrifuge is Japanese Shimadzu Corporation product, the visible grating spectrophotometer of 752Z, purchased from Shanghai the 3rd analytical tool factory.Tonotransducer LW-10 is purchased from Shanghai red flag instrucment and meter plant, and monitor TYPE-3066 is Japanese Shimadzu Corporation product.
Laboratory animal preparation and screening
By female KM mice with etherization, be fixed on operation plate, with 75% alcohol disinfecting, thorough excision bilateral ovaries, ligation is sewed up, after making it recover 1 week, subcutaneous injection estrogen and progestogen are promoted the sexual maturity, after it is emotionally stable, female mice is placed in male Mus covering box in 2: 1 ratios, and every day trains 10-15 minute, after treating that male Mus mating reaction is comparatively stable, according to the mating behavior number of times of continuous 5 days, male mice is divided into groups, make often to organize mice and straddle with number of copulations as far as possible close, react more weak and discard with nonresponder.
Embodiment 1 Rg1 is on the impact of mice sexual behaviour
Before experiment, mice trained, select, divide into groups, make often to organize mice sexual behaviour experience and copulation background is substantially identical, in every morning lumbar injection Rg1,10,5,25mg/kg once, female Mus is placed in male mouse cage by night, observes its sexual behaviour and namely straddles (mounting) and copulation (mating) number of times, and result proves Rg1 administration about 2 weeks, mice sexual behaviour significantly improves, and the results are shown in Figure 1a and 1b.
Embodiment 2 is on the impact of spongy body diastole effect
Confirm that three kinds of mechanism participate in the adjustment of spongy body rear screw angiosthenia, i.e. adrenergic, cholinergic and non-epinephrine, non-cholinergic (NANC), the latter is considered to the main frame mechanism of spongy body relaxing the VSM, and NO is the neurotransmitter of NANC, NO acts on bird adenosine cyclase (GC) and forms NO-GC complex, and combine with the porphyrin position of this enzyme, configuration is caused to change and activate GC, thus cGMP in cell is formed in a large number, this is the NO-cGMP path that one 5 genitals erection functions have close association, for this reason, we observe Rg1, on the impact of cGMP accumulation and NO release in spongy body diastole and spongy body.
The instrument medicine that we adopt MeCh (MCH) to discharge for endogenous NO observes Rg1 to the impact of the spongy body diastole effect that MCH mediate, and the diastole effect of result proof Rg1 to the spongy body that MCH mediates has obvious booster action, the results are shown in Table 1.
Table 1. ginsenoside Rg1 causes the impact of isolated rabbit spongy body diastole effect to MCH
Mean±s
10 μm of dSNP (sodium nitroprusside) and the in vitro spongy body that oneself smashes up endothelium are incubated 1 hour in 37 DEG C of temperature, cGMP is produced to stimulate spongy body, found that the cGMP of Rg1 group is significantly higher than matched group (table 2), prompting Rg1 has inhibitory action to phosphodiesterase (PDE).
Table 2. ginsenoside Rg1 is on the impact that mice cavernosal tissue NO discharges and IGMP gathers
Mean±s，
*P＜0.05，
**P＜0.01 vs Control
Embodiment 3
PDB5 (5 type PDE) in cyclic nucleotide phosphodiesterase (PDE) extended familys and reproductive system close relation, in the cavernosal tissue that it is mainly distributed in animal and platelet, take cGMP as specific substrate, GTP forms cGMP under GC effect, cGMP is hydrolyzed to 5 ' GMP through PDEs effect and lost efficacy, therefore suppress PDEs can make cGMP accumulation in spongy body, and then cause spongy body vasodilation, erection.
The ginsenoside that institute of materia medica of China provides, code name is: sldenafil: by DaLian, China, pfizer inc produces, lot number 25883002;
125i radioimmunity cGMp testing cassete is Amersham Products, lot number 60440504; PDE is Mark company gene recombinaton engineering product; Lot number: CA92039-2087; Produce in dimethyl sulfoxide (dimethylsmlphoxide, DMSO) Hong Sheng chemical plant; Lot number 950726.Instrument is GC-911 γ radiation immunity arithmometer (single probe, full-automatic) version number V2.1A, and Zhong Jia branch company of Creation Stock Co., Ltd of Chinese University of Science and Technology manufactures on April 16th, 2002.MTM Magnetic Isolation system system Amersham Products.
Method: according to Amersham company " ' I put exempt from testing cassete description operation.
Result
| CPM | Panaquilon's concentration (nmol/L) | CGMP concentration (fmol/L) |
| 4369 | 0 | 363.1 (PDE5 without inhibitors) |
| 3711 | 2.5 | 562.2 |
| 4151 | 5.0 | 419.5 |
| 3998 | 10.0 | 464.3 |
| 3854 | 20.0 | 510.9 |
| 4158 | 40.0 | 417.5 |
| CPM | Sldenafil concentration (nmol/L) | CGMP concentration (fmol/L) |
| 3854 | 0 | 510.9 (adding degeneration PDE5) |
| 3983 | 2.5 | 468.9 |
| 4282 | 5.0 | 384.7 |
| 4059 | 10.0 | 446.9 |
| 3931 | 20.0 | 485.3 |
| 3849 | 40.0 | 512.5 |
IC is calculated by logfit method
50for 7.24nmol/L, matched group sldenafil IC
50for 3.42nmol/L.
Design a pipe in experiment and add PDB5 without inhibitor, result C*MP concentration is 363.lfmol/L, another design one pipe adds degeneration PDES without inhibitor, and result cGMP concentration is 510.9fmol/L, suffices to show that rising to caused by panaquilon and sldenafil inhibitory action of cGMP concentration in experiment.Can show that panaquilon has thus suppress PDE5 effect and improve cGMP concentration, spongy body erection function be had to the facilitation of affirmative.
Claims (4)
1. ginsenoside Rg1 is for the preparation of the purposes prevented and/or treated in the product of male sexual disorder.
2. the purposes of claim 1, wherein said sexual dysfunction is erection disturbance.
3. pharmaceutical composition is for the preparation of the purposes prevented and/or treated in the product of male sexual disorder, and wherein said pharmaceutical composition comprises ginsenoside Rg1 monomer and excipient or carrier.
4. the purposes of claim 3, wherein said sexual dysfunction is erection disturbance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010543658.9A CN102000098B (en) | 2004-08-11 | 2004-08-11 | The purposes of ginsenoside Rg1 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410058310 CN1732963A (en) | 2004-08-11 | 2004-08-11 | The new purposes of ginsenoside Rg1 |
| CN201010543658.9A CN102000098B (en) | 2004-08-11 | 2004-08-11 | The purposes of ginsenoside Rg1 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410058310 Division CN1732963A (en) | 2004-08-11 | 2004-08-11 | The new purposes of ginsenoside Rg1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102000098A CN102000098A (en) | 2011-04-06 |
| CN102000098B true CN102000098B (en) | 2015-08-12 |
Family
ID=36075718
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010543658.9A Expired - Lifetime CN102000098B (en) | 2004-08-11 | 2004-08-11 | The purposes of ginsenoside Rg1 |
| CN 200410058310 Pending CN1732963A (en) | 2004-08-11 | 2004-08-11 | The new purposes of ginsenoside Rg1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410058310 Pending CN1732963A (en) | 2004-08-11 | 2004-08-11 | The new purposes of ginsenoside Rg1 |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN102000098B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101264096B (en) * | 2007-03-12 | 2011-11-09 | 中国医学科学院药物研究所 | Use of ginsenoside Rg1 in preparing spermatogenic product |
| US9314493B2 (en) | 2007-05-28 | 2016-04-19 | Amorepacific Corporation | Method for treating vascular inflammation, improving skin beauty and improving male sexual function using ginseng berry |
| KR20080104600A (en) * | 2007-05-28 | 2008-12-03 | (주)아모레퍼시픽 | Composition for treatment of ischemic heart disease, facilitation of blood circulation and angiogenesis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1353991A (en) * | 2000-11-18 | 2002-06-19 | 唐修文 | Ginsenoside enteric-coated tablet |
-
2004
- 2004-08-11 CN CN201010543658.9A patent/CN102000098B/en not_active Expired - Lifetime
- 2004-08-11 CN CN 200410058310 patent/CN1732963A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1353991A (en) * | 2000-11-18 | 2002-06-19 | 唐修文 | Ginsenoside enteric-coated tablet |
Non-Patent Citations (1)
| Title |
|---|
| 郝顺祖等.人参皂甙Rg1 对体外磷酸二酯酶5 活性的影响.《江苏大学学报(医学版)》.2004,第14卷(第1期),11-12. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1732963A (en) | 2006-02-15 |
| CN102000098A (en) | 2011-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Keeler et al. | Teratogenic compounds of Veratrum californicum (Durand). V. Comparison of cyclopian effects of steroidal alkaloids from the plant and structurally related compounds from other sources | |
| Gonçalves et al. | Behavior and brain enzymatic changes after long-term intoxication with cadmium salt or contaminated potatoes | |
| Ago et al. | Lithium attenuates methamphetamine-induced hyperlocomotion and behavioral sensitization via modulation of prefrontal monoamine release | |
| Zhang et al. | The effect of pyrroloquinoline quinone on apoptosis and autopha gy in traumatic brain injury | |
| Calixto et al. | Role of ventral hippocampal nitric oxide/cGMP pathway in anxiety-related behaviors in rats submitted to the elevated T-maze | |
| Sundblad et al. | Reduced extracellular levels of serotonin in the amygdala of androgenized female rats | |
| CN104664170A (en) | Feed additive for preventing fatty liver of largemouth bass | |
| Meotti et al. | Antinociceptive action of myricitrin: involvement of the K+ and Ca2+ channels | |
| Machtens et al. | Effects of various nitric oxide-donating drugs on adrenergic tension of human seminal vesicles in vitro | |
| Basak et al. | Evaluation of phytochemical and pharmacological activities of Bacopa monnieri (L.) | |
| CN102000098B (en) | The purposes of ginsenoside Rg1 | |
| Guadarrama-Enríquez et al. | Broccoli sprouts produce abdominal antinociception but not spasmolytic effects like its bioactive metabolite sulforaphane | |
| Wan et al. | Bisphenol A accelerates capacitation-associated protein tyrosine phosphorylation of rat sperm by activating protein kinase A | |
| Wang et al. | Integrated assessment of the spatial distribution, sources, degradation, and human risk of tetracyclines in honey in China | |
| Miltko et al. | Isolation and in vitro cultivation of the fibrolytic rumen ciliate Eremoplastron (Eudiplodinium) dilobum | |
| Saleem et al. | Inhibition of diet-restriction-induced behavioral deficits by tryptophan administration in rats. | |
| Emamuzo et al. | Effects of ethanol extract of leaves of Helianthus annus on the fecundity of Wistar rats | |
| Allouh et al. | Orchis anatolica root ingestion improves sexual motivation and performance in male rats | |
| Misztal et al. | The effect of allopregnanolone on enzymatic activity of the DNA base excision repair pathway in the sheep hippocampus and amygdala under natural and stressful conditions | |
| Alhaddad et al. | Estimation of LD50 and Acute Toxicity of Zygophyllum fabago in Mice | |
| GaloviÄ ovà et al. | The in vitro effect of the Origanum vulgare extract on semen | |
| Morakinyo et al. | Effects of aqueous extract of garlic (Allium sativum) on testicular functions in the rat | |
| CN102302018A (en) | Insecticidal composition including nitenpyram and matrine | |
| Yan et al. | Analysis of essential and toxic elements in jujube fruits collected from different locations in China | |
| Miozza et al. | Enhancement of carbachol-induced amylase secretion in parotid glands from rats with experimental periodontitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20150812 |
|
| CX01 | Expiry of patent term |